During Commercialization Sample Clauses

During Commercialization. In addition to the other responsibilities set forth in Section 2.4, in connection with Commercialization hereunder to the extent that Maxygen has exercised its Co-Promotion Option in accordance with Section 5.2 with respect to a given Product, the JPT shall, with respect to applicable Co-Promotion Countries for such Product, be responsible for: (i) coordinating design of pharmacoeconomic studies, and the use and dissemination of resulting Data with respect to the Co-Promotion Products (as defined hereinafter) within the Co-Promotion Countries; (ii) monitoring and reporting on the competitive landscape for the Co-Promotion Products within the Co-Promotion Countries; (iii) subject to the overview of the JSC, developing the strategy and plans for the Co-Promotion activities within the Co-Promotion Countries including strategies and plans for the Manufacture of Co-Promotion Products for such Commercialization purposes; (iv) coordinating branding, positioning and advertising plans and strategies (including but not limited to medical education, symposia, opinion leader development, peer-to-peer development, publications and journal ads) for Co-Promotion Products within the Co-Promotion Countries; (v) establishing, overseeing and coordinating the Co-Promotion activities of the Parties including sales force activities, such as training, the number of sales representatives and medical affairs personnel, territory alignment, and number and allocation of details, promotional materials, and the like for the Co-Promotion Products within the Co-Promotion Countries; (vi) reviewing material agreements (generally an agreement with an expense above a certain threshold determined by the JSC) with Third Parties to be entered into by either or both Parties with respect to Co-Promotion Products within the Co-Promotion Countries; and (vii) other matters related to the monitoring, review and coordination of Co-Promotion Products within the Co-Promotion Countries. In addition, the JPT shall facilitate the exchange of information regarding the planning, conduct and progress of Commercialization of Products for Exclusive Indications in the Territory and for Co-Development Indications for outside the Co-Promotion Countries, and provide a forum for discussion and coordination of such Commercialization activities with the Co-Development Activities.
Sample 1
AutoNDA by SimpleDocs
During Commercialization. If the Lead Marketing Party enters into a Partnering Agreement during the Collaboration Period, the Lead shall provide a copy of the Partnering Agreement to the Non-Lead promptly after such agreement is executed. The Non-Lead shall have [*] days, except as otherwise provided in Section 4.10(b)(iii), from receipt of the final, executed Partnering Agreement to notify the Lead in writing whether it will: (A) opt out of the Collaboration in the Partnered Territory or on a worldwide basis in accordance with Section 3.7(a)(ii) and receive royalties on Net Sales in the Partnered Territory or worldwide, if the opt-out is worldwide, excluding any country from which it has opted-out under Section 4.12, at a rate selected from the table set forth in Section 7.6(b) based on the stage of Development when such opt-out becomes effective, but subject to any applicable further reductions in the applicable royalty rate that apply under Sections 6.3(a), 7.6(d), 7.6(e) and 7.6(g) of this Agreement; or (B) continue as the Non-Lead and continue to be responsible for its Share of the Product Profit(Loss) during the Collaboration Period. If the Non-Lead fails to provide the Lead Development Party with written notice within the [*] day period, the Non-Lead is deemed to have elected to continue as the Non-Lead in accordance with clause (B).
Sample 1

Related to During Commercialization

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Diligence Upon receipt of the Marketing Authorization for a Licensed Product in the Field in a given Region in the Territory, Lian (directly, or through its Affiliates, Sublicensees or contractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such Region in the Territory. Lian will have sole decision-making authority and discretion with respect to Commercializing the Licensed Product in the Field in the Territory. [***].

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

Time is Money Join Law Insider Premium to draft better contracts faster.